EP Patent

EP2457563A1 — Zero-order modified release solid dosage forms

Assigned to Mallinckrodt LLC · Expires 2012-05-30 · 14y expired

What this patent protects

The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containg the pharmaceutical agent and a hydrophobic material; a modified release coating containing a hydrophilic pore-forming agent and …

USPTO Abstract

The invention comprises a solid dosage form for delivery of water soluble pharmaceutical agents. The solid dosage form comprises a matrix core containg the pharmaceutical agent and a hydrophobic material; a modified release coating containing a hydrophilic pore-forming agent and a hydrophobic polymer; and an overcoating surrounding the modified release coating. The dosage form exhibits a zero-order release profile upon dissolution.

Drugs covered by this patent

Patent Metadata

Patent number
EP2457563A1
Jurisdiction
EP
Classification
—
Expires
2012-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Mallinckrodt LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.